Concentrations of Soluble FMS-Like Tyrosine Kinase 1 and Placental Growth Factor Vary between Early- and Late-onset Preeclampsia
doi.org/10.26538/tjnpr/v6i3.2
Keywords:
Early-onset preeclampsia, Late-onset preeclampsia, Sflt-1, PIGF, Sflt-1/PIGFAbstract
Preeclampsia is a disease with a high mortality rate. The occurrence of preeclampsia based on onset can be detected by examining the biomarkers consisting of Soluble FMS-Like Tyrosine Kinase 1 (Sflt-1) and Placental Growth Factor (PIGF). This study was aimed at determining the concentrations and ratio of Sflt-1 to PIGF in early- and late-onset of preeclampsia. A cross sectional comparative study in General Center Hospital of DR. M. Djamil Padang, Pariaman Regional Hospital, Aisiyah Pariaman Hospital, and Padang Pariaman Regional Hospital was conducted for 2 years. Patients with early- and late-onset preeclampsia who satisfied the inclusion criteria and received treatment in the study sites during that time were recruited. Sampling was consecutive with 28 people per group. The enzyme-linked immunosorbent assay (ELISA) was used to evaluate the levels of Sflt-1 and PIGF. Data normality test was performed using the Shapiro-Wilk test and bivariate analysis with the Mann-Whitney test. The results indicated that there was a significant difference (p<0.05) between the mean levels of Sflt-1 at the early- and late-onset of preeclampsia with values of 8.69 and 5.61 ng/mL, respectively. Also, a significant difference between the mean early- and late-onset of PIGF levels was observed with values of 54.98 and 228.78 ng/mL, respectively. The mean early-onset of Sflt-1/PIGF ratio was 0.25 ng/mL, while a value of 0.5 ng/mL was recorded for the late-onset. The findings of the study revealed that there are differences in the levels of Sflt-1, PIGF, and the ratio of Sflt-1/PIGF between the early- and late-onset of preeclampsia.
References
Olaoye T, Oyerinde OO, Elebuji OJ, Ologun O. Knowledge, perception and management of pre-eclampsia
among health care providers in a maternity hospital. Int J Matern Child Health AIDS. 2019; 8(2):80-85.
Osungbade KO and Ige OK. Public health perspectives of preeclampsia in developing countries: implication for health
system strengthening. J Pregn. 2011; 1:1-6.
Diwan J, Shah C, Dixit R, Anand AK. A comparative study of serum uric acid level in normal pregnancy, and pregnancy induced hypertension. Int J Med Pub Health. 2011; 1(1):39-41.
Lisonkova S and Joseph KS. Incidence of preeclampsia: risk factors and outcomes associated with early-versus late-onset disease. Am J Obstet Gynecol. 2013; 209(6):544-552.
English FA, Kenny LC, McCarthy FP. Risk factors and effective management of preeclampsia. Integr Blood Press
Contr. 2015; 3(8):7-12.
Agrawal S, Cerdeira AS, Redman C, Vatish M. Metaanalysis and systematic review to assess the role of soluble FMS-like tyrosine kinase-1 and placenta growth factor ratio in prediction of preeclampsia: the SaPPPhirE study. Hypertens. 2018; 71(2):306-316.
Liu Y, Zhao Y, Yu A, Zhao B, Gao Y, Niu H. Diagnostic accuracy of the soluble Fms-like tyrosine kinase-1/placental growth factor ratio for preeclampsia: a meta-analysis based on 20 studies. Arch Gynecol Obstet. 2015; 292(3):507-518.
Sovio U, Gaccioli F, Cook E, Hund M, Charnock-Jones DS, Smith GC. Prediction of preeclampsia using the soluble
fms-like tyrosine kinase 1 to placental growth factor ratio: a prospective cohort study of unselected nulliparous women.
Hypertens. 2017; 69(4):731-738.
Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Dinkel C. Soluble fms-like tyrosine kinase-1-to-placental growth factor ratio and time to delivery in women with suspected preeclampsia. Obstet Gynecol. 2016; 128(2):261-269.
Rizos D, Eleftheriades M, Karampas G, Rizou M, Haliassos A, Hassiakos D, Vitoratos N. Placental growth factor and
soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational
age neonates: a longitudinal study. Eur J Obstet Gynecol Reprod Biol. 2013; 171(2):225-230.
Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H.
An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol. 2010; 202(2):161-171.
Daponte A, Pournaras S, Polyzos NP, Tsezou A, Skentou H, Anastasiadou F, Lialios G, Messinis IE. Soluble FMS-like tyrosine kinase-1 (sFlt-1) and serum placental growth factor (PlGF) as biomarkers for ectopic pregnancy and
missed abortion. J Clin Endocrinol Metab. 2011; 96(9):1444-1451.
George EM and Granger JP. Recent insights into the pathophysiology of preeclampsia. Expert Rev Obstet gynecol. 2010; 5(5):557-566.
Schneider S, Freerksen N, Röhrig S, Hoeft B, Maul H. Gestational diabetes and preeclampsia–similar risk factor
profiles?. Early Hum Dev. 2012; 88(3):179-184.
Pringle KG, Tadros MA, Callister RJ, Lumbers ER. The expression and localization of the human placental prorenin/renin-angiotensin system throughout pregnancy: roles in trophoblast invasion and angiogenesis? Placenta.
; 32(12):956-962.
Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annu Rev Pathol Mech. 2010; 28(5):173-
Sitepu M and Rachmadsyah J. Risk Factor and Biomarker of Preeclampsia. InPrediction of Maternal and Fetal
Syndrome of Preeclampsia. Intech Open. 2019; 10:1-15.
Kusanovic JP, Romero R, Chaiworapongsa T, Erez O, Mittal P, Vaisbuch E, Mazaki-Tovi S, Gotsch F, Edwin SS,
Gomez R, Yeo L. A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop
preeclampsia. J Matern Fetal Neonatal Med. 2009; 22(11):1021-1038.
Gathiram P and Moodley JJ. Pre-eclampsia: its pathogenesis and pathophysiolgy. . Cardiovasc. J Afr. 2016; 27(2):71-78.
Pijnenborg R, Vercruysse L, Hanssens M, Brosens I. Endovascular trophoblast and preeclampsia: A reassessment. Pregn Hypertens. 2011; 1(1):66-71.
Aksornphusitaphong A and Phupong V. Risk factors of early and late-onset pre‐eclampsia. J Obstet Gynaecol Res.
; 39(3):627-631.
Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi
SA. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006; 355(10):992-
Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H.
An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J
Obstet Gynecol. 2010; 202(2):161-171.
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
